OBJECTIVE: Postischemic reperfusion of the lung triggers proinflammatory responses that stimulate injurious neutrophil chemotaxis. We hypothesized that T lymphocytes are recruited and activated during reperfusion and mediate subsequent neutrophil-induced lung ischemia-reperfusion injury. METHODS: An in vivo mouse model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either the sham group (left thoracotomy) or 7 study groups that underwent 1-hour left hilar occlusion followed by 1 to 24 hours of reperfusion. After in vivo reperfusion, the lungs were perfused ex vivo with buffer whereby pulmonary function was assessed. Lung vascular permeability, edema, neutrophil accumulation, and cytokine/chemokine production (tumor necrosis factor alpha, interleukin 17, CCL3, and CXCL1) were assessed based on Evans blue dye leak, wet/dry weight ratio, myeloperoxidase level, and enzyme-linked immunosorbent assay, respectively. RESULTS: A preliminary study showed that 2 hours of reperfusion resulted in greater pulmonary dysfunction than 1 or 24 hours of reperfusion. The 2-hour reperfusion period was thus used for the remaining experiments. Comparable and significant protection from ischemia-reperfusion injury-induced lung dysfunction and injury occurred after antibody depletion of neutrophils or CD4(+) T cells but not CD8(+) T cells (P < .05 vs immunoglobulin G control). Lung ischemia-reperfusion injury was proportional to the infiltration of neutrophils but not T cells. Moreover, pulmonary neutrophil infiltration and the production of CXCL1 (KC) were significantly diminished by CD4(+) T-cell depletion but not vice versa. CONCLUSIONS: Both CD4(+) T lymphocytes and neutrophils accumulate during reperfusion and contribute sequentially to lung ischemia-reperfusion injury. The data suggest that neutrophils mediate ischemia-reperfusion injury; however, CD4(+) T cells play a critical role in stimulating chemokine production and neutrophil chemotaxis during ischemia-reperfusion injury.
OBJECTIVE: Postischemic reperfusion of the lung triggers proinflammatory responses that stimulate injurious neutrophil chemotaxis. We hypothesized that T lymphocytes are recruited and activated during reperfusion and mediate subsequent neutrophil-induced lung ischemia-reperfusion injury. METHODS: An in vivo mouse model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either the sham group (left thoracotomy) or 7 study groups that underwent 1-hour left hilar occlusion followed by 1 to 24 hours of reperfusion. After in vivo reperfusion, the lungs were perfused ex vivo with buffer whereby pulmonary function was assessed. Lung vascular permeability, edema, neutrophil accumulation, and cytokine/chemokine production (tumor necrosis factor alpha, interleukin 17, CCL3, and CXCL1) were assessed based on Evans blue dye leak, wet/dry weight ratio, myeloperoxidase level, and enzyme-linked immunosorbent assay, respectively. RESULTS: A preliminary study showed that 2 hours of reperfusion resulted in greater pulmonary dysfunction than 1 or 24 hours of reperfusion. The 2-hour reperfusion period was thus used for the remaining experiments. Comparable and significant protection from ischemia-reperfusion injury-induced lung dysfunction and injury occurred after antibody depletion of neutrophils or CD4(+) T cells but not CD8(+) T cells (P < .05 vs immunoglobulin G control). Lung ischemia-reperfusion injury was proportional to the infiltration of neutrophils but not T cells. Moreover, pulmonary neutrophil infiltration and the production of CXCL1 (KC) were significantly diminished by CD4(+) T-cell depletion but not vice versa. CONCLUSIONS: Both CD4(+) T lymphocytes and neutrophils accumulate during reperfusion and contribute sequentially to lung ischemia-reperfusion injury. The data suggest that neutrophils mediate ischemia-reperfusion injury; however, CD4(+) T cells play a critical role in stimulating chemokine production and neutrophil chemotaxis during ischemia-reperfusion injury.
Authors: S M Fiser; C G Tribble; S M Long; A K Kaza; J T Cope; V E Laubach; J A Kern; I L Kron Journal: J Thorac Cardiovasc Surg Date: 2001-06 Impact factor: 5.209
Authors: B Krishnadasan; B Naidu; M Rosengart; A L Farr; A Barnes; E D Verrier; M S Mulligan Journal: J Thorac Cardiovasc Surg Date: 2002-04 Impact factor: 5.209
Authors: Marc De Perrot; Yasuo Sekine; Stefan Fischer; Thomas K Waddell; Karen McRae; Mingyao Liu; Dennis A Wigle; Shaf Keshavjee Journal: Am J Respir Crit Care Med Date: 2002-01-15 Impact factor: 21.405
Authors: Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee Journal: J Immunol Date: 2003-11-15 Impact factor: 5.422
Authors: Ulrich Maus; Karen von Grote; William A Kuziel; Matthias Mack; Edmund J Miller; Josef Cihak; Manfred Stangassinger; Regina Maus; Detlef Schlöndorff; Werner Seeger; Jürgen Lohmeyer Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405
Authors: A A Abbas; J M Diamond; C Chehoud; B Chang; J J Kotzin; J C Young; I Imai; A R Haas; E Cantu; D J Lederer; K C Meyer; R K Milewski; K M Olthoff; A Shaked; J D Christie; F D Bushman; R G Collman Journal: Am J Transplant Date: 2016-11-04 Impact factor: 8.086
Authors: Daniel P Mulloy; Ashish K Sharma; Lucas G Fernandez; Yunge Zhao; Christine L Lau; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2013-03-28 Impact factor: 4.330
Authors: Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2016-04-22 Impact factor: 4.330
Authors: Matthew L Stone; Ashish K Sharma; Yunge Zhao; Eric J Charles; Mary E Huerter; William F Johnston; Irving L Kron; Kevin R Lynch; Victor E Laubach Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-04-24 Impact factor: 5.464
Authors: Ashish K Sharma; Victor E Laubach; Susan I Ramos; Yunge Zhao; George Stukenborg; Joel Linden; Irving L Kron; Zequan Yang Journal: J Thorac Cardiovasc Surg Date: 2009-11-11 Impact factor: 5.209